trending Market Intelligence /marketintelligence/en/news-insights/trending/J5OUIdT78iKK-02MaFVjUA2 content esgSubNav
In This List

Vertex Pharmaceuticals CFO steps down; interim named

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Vertex Pharmaceuticals CFO steps down; interim named

Vertex Pharmaceuticals Inc. said Thomas Graney resigned as CFO of the company.

Graney will continue as an employee of the company and will help in the transition until February 2019.

Ian Smith, the company's executive vice president, COO and former CFO, will act as interim CFO.

Boston-based Vertex develops therapies for various diseases, including cystic fibrosis, beta-thalassemia and sickle cell disease.